Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cyclacel Pharmaceuticals Inc CYCC

Alternate Symbol(s):  CYCCP

Healthcare Biotechnology
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic... see more

Recent & Breaking News (NDAQ:CYCC)

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

GlobeNewswire 6 days ago

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

GlobeNewswire 12 days ago

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

GlobeNewswire May 2, 2024

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire April 30, 2024

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

GlobeNewswire April 1, 2024

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 19, 2024

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire March 13, 2024

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

GlobeNewswire March 7, 2024

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

GlobeNewswire March 6, 2024

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

GlobeNewswire February 20, 2024

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

GlobeNewswire January 30, 2024

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

GlobeNewswire January 8, 2024

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

GlobeNewswire January 2, 2024

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire December 22, 2023

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

GlobeNewswire December 18, 2023

Cyclacel Pharmaceuticals Announces Reverse Stock Split

GlobeNewswire December 12, 2023

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

GlobeNewswire November 30, 2023

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

GlobeNewswire November 28, 2023

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

GlobeNewswire November 13, 2023

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

GlobeNewswire November 7, 2023